Skip to main content

SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY

Presentation of its Sycamore technology during a live surgical procedure

Fleurieux-sur-l’Arbresle – France – December 22, 2025 – 8am – Safe (FR001400ZU25 – ALSAF) announces its sponsorship of the 12th MAMMI International Meeting, whose theme was Diagnosis and Minimally Invasive Treatment of the Spine, held in Cagliari from December 9 to 11, 2025.

Chaired by Dr. Stefano Marcia, this landmark event brought together international experts to discuss the latest advances in minimally invasive spine treatment. The program included conferences, interactive sessions, and live surgical connections, allowing participants to observe the most innovative techniques in real time.

Demonstration of Sycamore technology

As part of this prestigious event, SAFE Orthopaedics presented its Sycamore technology during a live surgical procedure. This demonstration allowed participants to discover the concrete benefits of this innovative solution for spinal surgery.

“We are proud to support this international meeting, which actively contributes to knowledge sharing and innovation in our field,” said Nicolas Papillon, Deputy CEO of SAFE. “The MAMMI congress is an excellent platform for discussing best practices and cutting-edge technologies that benefit surgeons and patients.”

A leading international event

The MAMMI meeting has established itself as an unmissable event for professionals in the field of minimally invasive spinal surgery. This twelfth edition confirms its major role in disseminating cutting-edge techniques and continuously improving surgical practices.

About Safe Group

Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 people.
Safe Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United States.
For more information: www.safeorthopaedics.com

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile packaging.
For more information: www.safemedical.fr

Contact

SAFE GROUP                                                AELYON ADVISORS
investors@safeorthopaedics.com                        safe@aelyonadvisors.fr

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.